Skip to main content
. Author manuscript; available in PMC: 2020 Sep 21.
Published in final edited form as: Cell Rep. 2020 Sep 8;32(10):108102. doi: 10.1016/j.celrep.2020.108102

Figure 7. Working Model.

Figure 7.

Under normal conditions (normal), SAG is degraded by CDH1 at the G1 phase but inhibits APC/C at the M phase to ensure a timely progression of the cell cycle. Under a condition of high SAG (e.g., overexpression in cancer cells), SAG escapes from CDH1 degradation to accelerate the G1-to-S transition. Under a condition of low SAG (e.g., SAG inactivation by drug or siRNA), APC/C is prematurely activated to promote mitotic progression and slippage, leading to drug resistance.